Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Emphasizing the need to distinguish lobular and ductal carcinoma

Jason Mouabbi • 13 Dec 2024
SABCS 2024
Breast Cancer

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the distinct nature of invasive lobular carcinoma (ILC) compared to invasive ductal carcinoma (IDC). Both subtypes differ at the genomic, molecular, and microenvironmental levels, yet both have historically been grouped together. Dr Mouabbi consequently highlights the need for separate studies, scoring systems, and predictive tools, in this setting. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jason Mouabbi

ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more
1:40
ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more
Jason Mouabbi • 31 May 2025
Fostering partnerships between clinicians & patient advocates in breast cancer
1:32
Fostering partnerships between clinicians & patient advocates in breast cancer
Jason Mouabbi • 31 May 2025
How will neoadjuvant endocrine therapy improve outcomes in ILC?
0:28
How will neoadjuvant endocrine therapy improve outcomes in ILC?
Jason Mouabbi • 31 May 2025
Comparing NAET versus NAC in stage II/III ER+/HER2- invasive lobular carcinoma
0:59
Comparing NAET versus NAC in stage II/III ER+/HER2- invasive lobular carcinoma
Jason Mouabbi • 31 May 2025

Related Videos

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals